NASDAQ:XFOR

X4 Pharmaceuticals Q4 2025 Earnings Results & Report

X4 Pharmaceuticals logo
$3.04 +0.21 (+7.24%)
As of 02:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

X4 Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 17, 2026. The company reported EPS of -$0.22 versus the -$0.36 consensus estimate, while revenue of $2.57 million topped the $1.68 million estimate by $891 thousand.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

X4 Pharmaceuticals EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.36
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

X4 Pharmaceuticals Revenue Results

Actual Revenue
$2.57 million
Expected Revenue
$1.68 million
Beat/Miss
Beat by +$891.00 thousand
YoY Revenue Growth
N/A

X4 Pharmaceuticals Q4 2025 Earnings FAQ

X4 Pharmaceuticals (NASDAQ:XFOR) reported earnings of -$0.22 per share for Q4 2025, beating the consensus estimate of -$0.36. The report was announced on Tuesday, March 17, 2026.

X4 Pharmaceuticals reported revenue of $2.57 million for Q4 2025, against a consensus estimate of $1.68 million.

X4 Pharmaceuticals Earnings Headlines

Brookline Capital Markets Comments on XFOR FY2030 Earnings
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More X4 Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email.

About X4 Pharmaceuticals

X4 Pharmaceuticals (NASDAQ:XFOR) is a biopharmaceutical company focused on developing treatments for rare diseases involving dysfunction of the CXCR4 receptor, which plays a role in the movement of immune cells in the body.

Its lead medicine, mavorixafor, is marketed in the United States as Xolremdi. The U.S. Food and Drug Administration approved it in 2024 for people aged 12 and older with WHIM syndrome, a rare inherited condition that can leave patients vulnerable to infections.

X4 has also studied mavorixafor for other conditions associated with low levels of certain blood cells, including chronic neutropenia. The company’s work has centered on therapies that target CXCR4 to help improve immune-cell circulation.

View X4 Pharmaceuticals Profile